Introduction {#s1}
============

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with a higher risk of both local and distant recurrence and poor overall prognosis and it accounts for about 10--20% of all cases of breast cancer (Foulkes et al., [@B11]; Ovcaricek et al., [@B34]; Boyle, [@B5]). TNBC is characterized by a lack of the expression of estrogen receptor (ER), progesterone receptors (PR) and human epidermal growth factor receptor two (HER2/neu), thus, offers no validated molecular targets for treatment (Onitilo et al., [@B33]). The *BRCA1* and *BRCA2* genes are tumor-suppressor genes and involved in DNA damage repair and recombination, cell-cycle checkpoint control, apoptosis and transcriptional regulation (Venkitaraman, [@B37]). Mutations in *BRCA* genes induce defective DNA repair mechanisms, which are associated with the risk of development of breast and/or ovarian cancers (Peng et al., [@B35]). Some studies showed that *BRCA1* mutation (*BRCA1*^*Mu*t^) carriers were more likely to have ER-negative/PR-negative breast cancer (Musolino et al., [@B29]; Byrski et al., [@B6]; Kirk, [@B20]). In contrast, *BRCA2* mutation (*BRCA2*^*Mut*^) carriers seem to share the pathologic characteristics similar to those of patients with normal *BRCA* genes (non-carriers) (Noguchi et al., [@B31]). However, Comen et al. ([@B8]) found that the association between TNBC and *BRCA* mutations was not only limited to *BRCA1*, but also a significant proportion of women with TNBC had *BRCA2*^*Mut*^. Currently, the relationship between the status of *BRCA* mutation and the statuses of ER, PR, HER2/neu and P53 have been inconsistent (Maegawa and Tang, [@B26]; Wu et al., [@B38]). With the development of targeted therapies for breast cancer patients, designation of treatment regimens has become more specific, and breast cancer patients with *BRCA* mutations should be treated differently from the patients without *BRCA* mutations. Therefore, the exact relationship between BRCA status and TNBC needs to be further investigated and validated.

We therefore performed a meta-analysis to investigate the association between the status of *BRCA* mutations and TNBC and the effect of *BRCA*^*Mut*^ on nuclear grade and tumor size in patients with breast cancer.

Materials and methods {#s2}
=====================

Data sources and search strategy
--------------------------------

We systematically searched the databases of MEDLINE (PubMed, <http://www.ncbi.nlm.nih.gov/pubmed/>), Embase (<http://www.embase.com>), and Cochrane Library ([www.cochranelibrary.com](http://www.cochranelibrary.com)) for relevant publications of primary studies, and used the following search algorithm: breast cancer, breast carcinoma, mammary cancer, breast tumor and *BRCA1* or *BRCA2, BRCA*, and triple negative breast cancer, TNBC or molecular typing, type or subtype of breast cancer. The databases were searched for the studies published from April, 1959 to November, 2017.

Study selection
---------------

The inclusion criteria were as follows: (a) comparative studies of breast cancer patients with *BRCA1*^*Mut*^, *BRCA2*^*Mut*^, and non-carriers; (b) studies were published as a full paper in English; (c) the statuses of ER, PR and HER2 were measured by immunohistochemistry; and (d) high-quality case-control studies (Newcastle-Ottawa Scale \[NOS\] score ≥ 7 points). The exclusion criteria were as follows: (a) review articles; (b) study was based on preclinical setting such as cell culture and/or animal models of feline mammary cancer; (c) study did not discuss *BRCA1* and *BRCA2* mutations separately; and (d) study had no inclusion, or duplicated data from other studies.

Data extraction
---------------

Two investigators independently extracted the date from each study including the first author; year of publication; country of study; numbers of subjects with (a) non-carrier with TNBC, (b) non-carriers without TNBC, (c) *BRCA1*^*Mut*^ carrier with TNBC, (d) *BRCA1*^*Mut*^ carrier without TNBC, (e) *BRCA2*^*Mu*t^ with TNBC and (f) *BRCA2*^*Mut*^ carrier without TNBC; tumor size and nuclear grade with a standardized form. Additional investigators were consulted when discrepancies were present.

Population, interventions, comparators, outcomes and study designs (PICOS)
--------------------------------------------------------------------------

The population from the study is patients with breast cancer. Genetic testing of *BRCA* mutations was performed in these patients. *BRCA* status (*BRCA1* mutations carriers, *BRCA2* mutations carriers, and non-carriers) was compared and the outcomes of incidence of TNBC, expression of nuclear grade and tumor burden (\>2 cm) were evaluated in these patients. The study designs were to evaluate the association between *BRCA* status and TNBC as well as the relationship of *BRCA* mutations and the expression of nuclear grade and tumor burden.

Quality assessment
------------------

The quality of each study was independently evaluated by at least two examiners who read each study and scored it according to the NOS criteria (Deeks et al., [@B9]). The average NOS score was 7.4 points.

Statistical analysis
--------------------

The STATA software version 12.0 (Stata Corp, College Station, TX, USA) was used to perform this meta-analysis. Dichotomous outcomes were analyzed using the OR with 95% CI as the summary statistics, as previously described in the Mantel--Haenszel method (Mantel and Haenszel, [@B27]; Greenland and Robins, [@B15]). Statistical heterogeneity was evaluated by a *X*^2^ test (Higgins et al., [@B18]). The Higgins *I*^2^ test measured inconsistency between studies; values of \<25, 25--50, and \>50% were defined as low, moderate and high, respectively (DerSimonian and Laird, [@B10]). Data were analyzed with the fixed-effect model for low or moderate consistency and with the random-effect model for high heterogeneity. We also performed sensitivity analysis by omitting specific studies to find potential outliers.

Results {#s3}
=======

Study selection and patient characteristics
-------------------------------------------

A total of 527 publications were identified from the three databases, 219 from PubMed, 303 from Embase, and five from Cochrane Library. The titles and abstracts of all remaining publications (*n* = 349) were reviewed after removing the duplicate publications (*n* = 178) and 307 more publications were excluded as irrelevant to the topic. Next, 26 publications were further excluded for insufficient data (*n* = 15), feline mammary focus (*n* = 2), and non-original research (*n* = 9) after carefully examining the full texts of the remaining 42 publications. Finally, 16 eligible publications were included in the study of meta-analysis (Haffty et al., [@B17]; Atchley et al., [@B3]; Kwong et al., [@B22]; Arun et al., [@B2]; Comen et al., [@B8]; Gonzalez-Angulo et al., [@B14]; Xu et al., [@B39]; Noh et al., [@B32]; Li et al., [@B25]; Yu et al., [@B41]; Zugazagoitia et al., [@B42]; Aleskandarany et al., [@B1]; Gabaldó Barrios et al., [@B12]; Ghouadni et al., [@B13]; Ha et al., [@B16]; Krammer et al., [@B21]). The screening method and results of the relevant studies are shown in Figure [1](#F1){ref-type="fig"} and the main characteristics of participated patients are summarized in Table [1](#T1){ref-type="table"}.

![Flow chart for study selection.](fphar-09-00909-g0001){#F1}

###### 

The main characteristics of patients included in the studies.

  **First author**   **Country/region**   **Year**   **Median age (year)**   ***BRCA1**^***Mut***^**(*****n*****)***   ***BRCA2**^***Mut***^**(*****n*****)***   **Non-carrier (*****n*****)**                 
  ------------------ -------------------- ---------- ----------------------- ----------------------------------------- ----------------------------------------- ------------------------------- ----- ------- --------
  Haffty             USA                  2006       NA (NA)                 8                                         2                                         1                               6     13      29
  Atchley            USA                  2008       43 (21--75)             32                                        24                                        7                               23    54      337
  Kwong              Hong Kong            2009       42 (21--82)             8                                         4                                         6                               11    45      131
  Comen              USA                  2011       57.1(NA)                19                                        6                                         6                               15    39      364
  Arun               USA                  2011       40 (21--73)             33                                        19                                        2                               21    NA      NA
  Gonzalez-Angulo    USA                  2011       51 (27--83)             12                                        62                                        3                               62    NA      NA
  Xu                 China                2011       50.6 (29--76)           28                                        24                                        8                               20    40      232
  Noh                Korea                2013       40 (28--52)             16                                        9                                         6                               16    30      143
  Yu                 Korea                2014       NA (12--96)             49                                        31                                        13                              88    6,842   34,758
  Zugazagoitia       Spain                2014       32 (NA)                 7                                         5                                         1                               7     NA      NA
  Li                 China                2014       39.7 (24-64)            18                                        78                                        7                               78    NA      NA
  Aleskandarany      UK                   2015       42 (NA)                 31                                        15                                        2                               25    297     1552
  Krammer            Germany              2017       44.1(24--82)            128                                       99                                        26                              185   NA      NA
  Ha                 Korea                2017       39.7(25--72)            52                                        47                                        27                              76    NA      NA
  Ghouadni           France               2017       52 (38--58)             18                                        8                                         3                               10    NA      NA
  Gabaldó Barrios    Spain                2017       NA                      25                                        13                                        8                               32    43      252

*n, number; NA: not applicable*.

The included studies were conducted in eight countries or regions as USA 5, Korea 3, China 2, Hong Kong 1, UK 1, Germany 1, France 1, and Spain 2, the published date was between 2006 and 2017. 45,870 patients were included in the studies, with the median age ranged from 32.0 to 57.1 years, 868 *BRCA1*^*Mut*^ carriers, 739 *BRCA2*^*Mut*^ carriers, and 45,263 non-carriers (Table [1](#T1){ref-type="table"}).

Association of *BRCA* status and TNBC
-------------------------------------

We found that *BRCA1*^*Mut*^ carriers were more likely to have TNBC than those of *BRCA2*^*Mut*^ carriers (OR: 3.292; 95% CI: 2.773--3.909) or non-carriers (OR: 8.889; 95% CI: 6.925--11.410) among the patients with breast cancer (Figure [2](#F2){ref-type="fig"}). Because heterogeneity was found across the studies (*I*^2^ = 35.2%, heterogeneity *X*^2^ = 23.16; d.f. = 15; *P* = 0.081), the pooled OR was calculated as 3.292 (95% CI: 2.773--3.909) by a fixed-effect model. Furthermore, *BRCA1*^*Mut*^ carriers were significantly more likely to have TNBC than those of non-carriers (Figure [3](#F3){ref-type="fig"}). There was significant heterogeneity in the studies (*I*^2^ = 59.9%, heterogeneity *X*^2^ = 19.94; d.f. = 8; *P* = 0.011), the pooled OR was calculated as 4.011 (95% CI: 3.362--4.786) by a fixed-effect model. Interestingly, the incidence of TNBC was not significantly different between *BRCA2*^*Mut*^ carries and non-carriers (Figure [4](#F4){ref-type="fig"}). Because the studies were significantly heterogeneous (*I*^2^ = 48.0%, heterogeneity *X*^2^ = 15.39; d.f. = 8; *P* = 0.052), the pooled OR was calculated as 1.188 (95% CI: 0.929--1.518) by a random-effects model.

![The odds ratio (OR) of *BRCA1* mutations vs. *BRCA2* mutations in patients with TNBC by Forest Plot.](fphar-09-00909-g0002){#F2}

![The odds ratio (OR) of *BRCA1* mutations vs. non-carriers in patients with TNBC by Forest Plot.](fphar-09-00909-g0003){#F3}

![The odds ratio of *BRCA2* mutations vs. non-carriers in patients with TNBC by Forest Plot.](fphar-09-00909-g0004){#F4}

Association of *BRCA* status and nuclear grade or tumor burden
--------------------------------------------------------------

As shown in Table [2](#T2){ref-type="table"}, high expression of nuclear grade was more common in the breast cancer patients with *BRCA1*^*Mut*^ carriers than those of patients with *BRCA2*^*Mut*^ carriers (OR: 2.663; 95% CI: 1.731--4.097; *P* = 0.211). Moreover, Tumors were more likely to exceed 2 cm in the breast cancer patients with *BRCA1*^*Mut*^ carriers than those of patients with *BRCA2*^*Mut*^ *carriers* (OR: 1.577; 95% CI: 1.067--2.331; *P* = 0.157).

###### 

Associations between *BRCA* mutation status and tumor size or nuclear grade.

  **First author**   ***BRCA1**^***Mut***^**(*****n*****)***   ***BRCA2**^***Mut***^**(*****n*****)***   ***BRCA1**^***Mut***^**(*****n*****)***   ***BRCA2**^***Mut***^**(*****n*****)***   **NOS**                     
  ------------------ ----------------------------------------- ----------------------------------------- ----------------------------------------- ----------------------------------------- --------- ----- ----- ----- ---
  Haffty             NA                                        NA                                        NA                                        NA                                        NA        NA    NA    NA    8
  Atchley            NA                                        NA                                        NA                                        NA                                        NA        NA    NA    NA    8
  Kwong              6                                         18                                        7                                         2                                         NA        NA    NA    NA    7
  Comen              NA                                        NA                                        NA                                        NA                                        NA        NA    NA    NA    7
  Arun               6                                         51                                        5                                         18                                        10        45    11    10    8
  Gonzalez-Angulo    NA                                        NA                                        NA                                        NA                                        NA        NA    NA    NA    7
  Xu                 11                                        41                                        8                                         20                                        20        32    14    14    7
  Noh                15                                        10                                        25                                        7                                         6         19    20    12    7
  Yu                 37                                        38                                        54                                        38                                        20        30    33    29    7
  Zugazagoitia       6                                         18                                        7                                         2                                         NA        NA    NA    NA    7
  Li                 NA                                        NA                                        NA                                        NA                                        NA        NA    NA    NA    7
  Aleskandarany      24                                        24                                        11                                        16                                        NA        NA    NA    NA    8
  Krammer            NA                                        NA                                        NA                                        NA                                        65        160   110   105   7
  Ha                 49                                        40                                        41                                        53                                        45        54    66    37    7
  Ghouadni           NA                                        NA                                        NA                                        NA                                        NA        NA    NA    NA    7
  Gabaldó Barrios    NA                                        NA                                        NA                                        NA                                        NA        NA    NA    NA    7

*TS, tumor size; NG, nuclear grade; NOS, new castle-ottawa Scale; n, number; NA, not applicable*.

Sensitivity analyses and publication bias
-----------------------------------------

Sensitivity analyses showed that two publications from Li et al. ([@B25]) and Xu et al. ([@B39]) accounted for all the observed heterogeneity. The *I*^2^ was 34.5% when all studies were included in the analysis. However, the *I*^2^ was reduced to 20.5% when the study of Li et al. ([@B25]) was excluded and it was further dropped to 18.1% when the study of Yu et al. ([@B41]) was also removed from the analysis. The results suggest that those two papers significantly influenced the overall analysis. Begg\'s tests indicated that no publication bias was observed in this meta-analysis for association between *BRCA1*^*Mut*^ and *BRCA2*^*Mut*^ (*P* = 0.499; Figure [5](#F5){ref-type="fig"}), or between *BRCA1*^*Mut*^ and non-carriers (*P* = 0.348; Figure [6](#F6){ref-type="fig"}).

![Indication of publication bias for the association between *BRCA1* mutations and *BRCA2* mutations by Begg\'s Funnel Plot with pseudo 95% confidence limits. The data indicate that there was no obvious indication of publication bias.](fphar-09-00909-g0005){#F5}

![Indication of publication bias for the association between *BRCA1* mutations and non-carriers by Begg\'s Funnel Plot with pseudo 95% confidence limits. The data indicate that there was no obvious indication of publication bias.](fphar-09-00909-g0006){#F6}

Discussion {#s4}
==========

We investigated the association between *BRCA* status and TNBC (a subtype of breast cancer) and the characteristics of breast cancer patients with *BRCA1*^*Mut*^ and *BRCA2*^*Mut*^ using a meta-analysis. The currently specific criteria of guidelines from the National Comprehensive Cancer Network (NCCN) for test of *BRCA1*^*Mut*^ and *BRCA2*^*Mut*^ include patients\' ages at diagnosis and their family members; family histories of breast, ovarian, pancreatic and prostate cancers, and diagnosed TNBC (National Comprehensive Cancer Network, [@B30]). Up to date, approximately 300 mutations within the *BRCA1*^*Mut*^ gene have been identified, including small insertions, deletions and non-sense mutations, most of them lead to functionally inactive proteins (Miki et al., [@B28]; Simard et al., [@B36]). *BRCA2* is a tumor suppressor gene that mediates the repair of chromosomal damage (Yoshida and Miki, [@B40]). In the present study of meta-analysis, we found that TNBC was more common among the breast cancer patients with *BRCA1*^*Mut*^ than those of patients with *BRCA2*^*Mut*^ (OR: 3.292; 95% CI: 2.773--3.909) or non-carriers (OR: 8.889; 95% CI: 6.925--11.410). In an unselected cohort study in 77 patients with TNBC, it was found that 15 (19.5%) had *BRCA* mutations including 12 (15.6%) in *BRCA1* (one somatic) and 3 (3.9%) in *BRCA2* (Gonzalez-Angulo et al., [@B14]). In addition, a significantly lower risk of relapse was found in TNBC patients with *BRCA* mutations (Gonzalez-Angulo et al., [@B14]).

The underlying mechanism that links *BRCA1*^*Mut*^ to ER negativity has been the focus of ongoing investigations. Hosey et al. ([@B19]) discovered that *BRCA1*^*Mut*^ tumors fail to express ER due to the loss of *BRCA1*-mediated transcriptional activation of estrogen receptor 1 (ESR1). Reduction or absence of *BRCA1* in breast cancer occurs through several mechanisms including hypermethylation of the *BRCA1* promoter, loss of heterozygosity, and transcriptional regulation of *BRCA1* (Catteau et al., [@B7]; Baldassarre et al., [@B4]). However, the exact mechanism for the transcription of *BRCA1* is highly complex and remains unknown. Further studies are needed to gain insight into the interaction between *BRCA1* and ER, and its potential effects on the expressions of PR and HER2.

*BRCA2*^*Mut*^ breast cancer has the pathologic features similar to those of sporadic breast cancers (Lee et al., [@B23]). The incidence of TNBC was not significantly different between patients with *BRCA2*^*Mut*^ and non-carriers (OR: 1.203; 95% CI: 0.871--1.660). Hosey et al. ([@B19]) suggested that breast cancer patients with *BRCA2*^*Mut*^ were unlikely to be ER-deficient because of the ability of estrogen metabolites to induce loss of the second *BRCA1* allele, thus, estrogen may somehow facilitate the survival of *BRCA1*-deficient cells in hormonally responsive tissues.

Interestingly, in the present study, we found that a high nuclear grade was also more common in the tumors from *BRCA1*^*Mut*^ patients than in those of patients with *BRCA2*^*Mut*^ carriers (OR 2.663; 95% CI: 1.731--4.097; *P* = 0.211) and the tumors with *BRCA1*^*Mut*^ were more likely to have nuclear grade three than those of tumors with *BRCA2*^*Mut*^. This finding is consistent with the earlier studies in the literature (Musolino et al., [@B29]; Li et al., [@B24]; Xu et al., [@B39]). We also found that the tumors with *BRCA1*^*Mut*^ were more likely to exceed 2 cm than those of tumors with *BRCA2*^*Mut*^ (\$OR 1.577; 95% CI: 1.067--2.331), although several studies have reported that the sizes of tumors were not significantly different between the tumors with *BRCA1*^*Mut*^ and the tumors with *BRCA2*^*Mut*^ (Xu et al., [@B39]; Noh et al., [@B32]; Yu et al., [@B41]). The observed difference of tumor size may be due to different clinical and pathological characteristics from the tumors with *BRCA1*^*Mut*^ and *BRCA2*^*Mut*^ leading to different prognosis in the patients with *BRCA* mutations. The findings may be significant with valuable information for oncologists to better understand the role of *BRCA* mutations in breast cancer patients and optimal treatment of TNBC.

Some limitations of the study should be acknowledged in this meta-analysis. The methods of assessing ER/PR-negative status were varied among the studies. Most studies defined ER/PR-negative specimens as having \<10% immunoreactive cells, whereas newer immunohistochemistry guidelines have used a threshold of \<1%. *BRCA* mutation tests also lack uniformity, which may affect the outcomes. Therefore, selection bias was inevitable.

Conclusion {#s5}
==========

The present study suggests that TNBC was more common among the breast cancer patients with *BRCA1*^*Mut*^ tumors than those of patients with *BRCA2*^*Mut*^ tumors or non-carriers. Furthermore, a high expression of nuclear grade and large tumor burden (\> 2cm) were significantly more common in *BRCA1*^*Mut*^ patients than that of *BRCA2*^*Mut*^ patients. The study provides valuable information for clinicians to better understand the role of *BRCA* mutations in breast cancer patients for providing optimal treatment and improving outcome clinically.
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